Design Therapeutics DSGN
NASDAQ DSGN
$10.78 +0.13 (+1.22%)
As of: Nov 11, 2026 · 3:37 PM EST

Design Therapeutics (DSGN) Return on Sales [ROS] (2020)

Updated

Design Therapeutics' Return on Sales [ROS] was -11700.00% in Q4 2020, up 215.00 percentage points from the prior quarter.

Analysis

Design Therapeutics (DSGN) Return on Sales [ROS] (2020) Analysis & Trends

For FY2020, Return on Sales [ROS] at Design Therapeutics came in at -3685.84%.

  • Quarterly Return on Sales [ROS] has moved between -11915.00% (Q3 2020) and -438.73% (Q1 2020) over five years.
  • Per Business Quant data, DSGN's Return on Sales [ROS] in the three quarters before Q4 2020 was -11915.00% (Q3 2020), -4719.35% (Q2 2020) and -438.73% (Q1 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Design Therapeutics 679.31 Mn -179.36 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 -11,700.00%
Sep 30, 2020 -11,915.00%
Jun 30, 2020 -4,719.35%
Mar 31, 2020 -438.73%
API Access

Design Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=DSGN&period=max&api_key=YOUR_API_KEY